Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd has reported a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales have shown robust growth, profitability metrics and earnings per share continue to face headwinds, reflecting a complex financial landscape for this micro-cap player in the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹330.86 crores, reported a shocking loss of ₹0.01 crores for Q4 FY26, marking a complete reversal from the ₹0.94 crores profit posted in Q4 FY25. The stock plunged 7.87% on May 5, 2026, closing at ₹174.45, as investors reacted to an extraordinary tax charge that exceeded the company's pre-tax profit—a rare accounting anomaly that signals potential earnings quality concerns.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 183.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nath Bio-Genes (India) Ltd locked at its upper circuit of 10.53% on 13 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The micro-cap agricultural products company’s recent performance and valuation metrics have prompted a reassessment across quality, valuation, financial trend, and technical parameters, signalling cautious optimism for investors.

Nath Bio-Genes (India) Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s performance and outlook.

For the second consecutive session, Nath Bio-Genes (India) Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 127 on 30 Mar 2026, marking a 5.85% decline over two days amid broader market weakness.

A sharp decline in Nath Bio-Genes (India) Ltd has pushed the stock to a fresh 52-week low of Rs 129.15 on 27 Mar 2026, marking a significant 5% intraday drop and extending the recent downtrend despite a brief two-day rally.

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has been downgraded from a Sell to a Strong Sell rating as of 23 March 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, weak long-term fundamentals, and a cautious valuation outlook, signalling heightened risks for investors amid ongoing market pressures.

A sharp decline of 3.61% today dragged Nath Bio-Genes (India) Ltd to a fresh 52-week low of Rs 135, extending a downward trajectory that has seen the stock underperform the broader market significantly over the past year.

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The company’s micro-cap status, flat recent financial performance, and subdued institutional interest continue to weigh on sentiment, while modest improvements in technical indicators have prompted a cautious reassessment of its market stance.

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 16 March 2026, providing an up-to-date view of the company’s position in the market.

Nath Bio-Genes (India) Ltd touched a fresh 52-week low of Rs.136 on 9 Mar 2026, marking a significant decline amid ongoing challenges reflected in its financial performance and market positioning. The stock’s fall comes despite a brief two-day rally, underscoring persistent pressures within the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd has been downgraded from a Sell to a Strong Sell rating as of 4 March 2026, reflecting deteriorating technical indicators, flat financial performance, and waning investor confidence. The company’s Mojo Score has dropped to 26.0, signalling significant caution for investors amid persistent underperformance relative to benchmarks and peers.

Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has touched a new 52-week low of Rs.137.95, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures.